Recent events
Recent events tied to this brand in public sources.
Back to profile4 entries
2021
Protalix reports first-quarter 2021 financial results
Protalix BioTherapeutics reported financial results for the first quarter ended March 31, 2021, including revenue of $4.5 million and a net loss of approximately $5.5 million.
2020
Protalix announces Yael Hayon's appointment as VP of Research and Development
On June 8, 2020, Protalix announced Yael Hayon's appointment as Vice President, Research and Development, effective July 5, 2020.
2020
Protalix announces R&D executive retirement
Protalix BioTherapeutics stated that Yoseph Shaaltiel retired from his Executive Vice President, Research and Development position on June 2, with the retirement effective June 15, 2020.
2019
Protalix announces two board appointments
Protalix announced the appointment of Pol F. Boudes and Gwen A. Melincoff to its Board of Directors, effective January 1, 2020.